Optimising levodopa therapy for the management of Parkinson's disease (Q36285098)

13 August 2017

1 reference

title

Optimising levodopa therapy for the management of Parkinson's disease (English)

1 reference

13 August 2017

1 reference

1 reference

Fabrizio Stocchi

1

0 references

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

252 Suppl 4

1 reference

13 August 2017

IV43-IV48

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-005-4009-4

13 August 2017

0 references

cites work

Levodopa/carbidopa/entacapone (Stalevo).

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-4009-4

Levodopa strengths and weaknesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-4009-4

Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-4009-4

New developments in levodopa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-4009-4

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-4009-4

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-4009-4

Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-4009-4

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

21 January 2018

1 reference

12 December 2020

Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism

1 reference

12 December 2020

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

12 December 2020

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

1 reference

12 December 2020

Molecular basis of levodopa-induced dyskinesias.

1 reference

12 December 2020

Neurotoxicity of levodopa on catecholamine-rich neurons

1 reference

12 December 2020

The role of COMT inhibition in the treatment of Parkinson's disease

1 reference

12 December 2020

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

1 reference

12 December 2020

Toxic and protective effects of L-dopa on mesencephalic cell cultures

1 reference

12 December 2020

Unmet medical needs in Parkinson's disease

1 reference

12 December 2020

Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line

1 reference

12 December 2020

1 reference

12 December 2020

Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms

1 reference

12 December 2020

Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease.

1 reference

12 December 2020

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

12 December 2020

Clinical-pathological study of levodopa complications

1 reference

12 December 2020

Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development

1 reference

12 December 2020

Parkinson's disease. Second of two parts

1 reference

12 December 2020

Apomorphine and lisuride infusion. A comparative chronic study

1 reference

12 December 2020

Continuous dopaminergic stimulation in early and advanced Parkinson's disease

1 reference

12 December 2020

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

12 December 2020

The role of dopamine agonists in the treatment of early Parkinson's disease

1 reference

12 December 2020

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

1 reference

12 December 2020

Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group

1 reference

12 December 2020

Nonmotor fluctuations in Parkinson's disease: frequent and disabling

1 reference

12 December 2020

Treatment interventions for Parkinson's disease: an evidence based assessment

1 reference

12 December 2020

Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid.

1 reference

12 December 2020

Rapid treatment of "wearing off" in Parkinson's disease.

1 reference

12 December 2020

Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.

1 reference

12 December 2020

Re: Cabergoline versus levodopa monotherapy: a decision analysis

1 reference

12 December 2020

Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro

1 reference

12 December 2020

Levodopa and the progression of Parkinson's disease

1 reference

12 December 2020

L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation.

1 reference

12 December 2020

Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease

1 reference

12 December 2020

Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration

1 reference

12 December 2020

Strategies to modify levodopa treatment.

1 reference

12 December 2020

An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off

1 reference

12 December 2020

Treating motor fluctuations with controlled-release levodopa preparations.

1 reference

12 December 2020

The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

1 reference

12 December 2020

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

12 December 2020

Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies

1 reference

12 December 2020

Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.

1 reference

12 December 2020

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease

1 reference

12 December 2020

L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress.

1 reference

12 December 2020

Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons

1 reference

12 December 2020

1 reference

12 December 2020

Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease

1 reference

12 December 2020

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

1 reference

12 December 2020

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease

1 reference

12 December 2020

Astrocytes protect neurons from hydrogen peroxide toxicity

1 reference

12 December 2020

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

12 December 2020

L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects

1 reference

12 December 2020

Continuous dopamine-receptor stimulation in early Parkinson's disease

1 reference

12 December 2020

The evolution and origin of motor complications in Parkinson's disease

1 reference

12 December 2020

Twelve-month safety of entacapone in patients with Parkinson's disease

1 reference

12 December 2020

Nonmotor fluctuations in patients with Parkinson's disease

1 reference

12 December 2020

Levodopa: why the controversy?

1 reference

12 December 2020

Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations

1 reference

12 December 2020

Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.

1 reference

12 December 2020

Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity.

1 reference

12 December 2020

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

1 reference

12 December 2020

10.1007/S00415-005-4009-4

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16222437